According to filings with the U.S. Securities and Exchange Commission, Hyperion Surgical is raising up to $23,714,921.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Hyperion Surgical
Hyperion Surgical is a medical technology company focused on transforming vascular access procedures by combining advanced imaging, robotics, and intelligent software into an integrated platform. According to its website, the companys Ivy robotic vascular access system is designed to make intravenous (IV) catheter placement more predictable, consistent, and less stressful for both clinicians and patients by automating and guiding key steps in the workflow. Hyperion Surgical positions itself as an innovator in robotic-assisted vascular access, emphasizing improved precision, safety, and efficiency in complex IV placement scenarios. The company highlights a clinician-centered design philosophy, aiming to support healthcare professionals with tools that enhance confidence and reliability in bedside procedures. Overall, Hyperion Surgicals primary business is the development of cutting-edge robotic and AI-enabled solutions that simplify and standardize vascular access, with a clear focus on improving patient experience and clinical outcomes.

To learn more, visit https://www.hyperionsurgical.com/
LinkedIn: https://www.linkedin.com/company/hyperion-surgical-inc

Contact:
Eric Peterson, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.